Stang PE, Gardner J. 2005. ‘Epidemiology and pharma-
coeconomic research’. InPrinciples of Pharmacoe-
conomics, Bootman JL, Townsend RJ, McGhan WF
(eds). Cincinnati, OH: Harvey Whitney Books Co.
Uhl K, Kennedy DL, Kweder SL. 2002. ‘Risk manage-
ment strategies in the Physicians’ Desk Reference
product labels for pregnancy category X drugs’.
Drug Safety 25 : 885–892.
Waller P. 2003. ‘Dealing with uncertainty in drug
safety: lessons for the future from sertindole’.Phar-
macoepidemiol. Drug Safety 12 : 283–287, 289–290.
Weatherby LB, Nordstrom BL, Fife D, Walker AM.
- ‘The impact of wording in ‘‘Dear doctor’’
letters and in black box labels’.Clin. Pharmacol.
Ther. 72 : 735–742.
Wehnert A. 1998. ‘The European Post-marketing obser-
vational Serdolect (EPOS) project: increasing our
understanding of schizophrenia therapy’.Int. Clin.
Psychopharmacol. 13 (Suppl. 3): S27–S30.
Wilkinson JJ, Force RW, Cady PS. 2004. ‘Impact of
safety warnings on drug utilization: marketplace
lifespan of cisapride and troglitazone’. Pharma-
cotherapy 24 : 978–986.
World Health Organization. 2001. ‘WHO Expert Com-
mittee on drug dependence: thirty-second report’.
WHO Tech. Rep. Ser. 903 : i–v, 1–26.FURTHER READING 563